Overweight-obese patients have more frequent chemotherapy dose reductions during neoadjuvant chemotherapy (NAC) for breast cancer when compared to normal weight patients, and this reduction in obese patients was a predictor of not attaining pathologic complete response (pCR). This according to a study of 171 patients with operable breast cancer who received NAC; 112 of whom were overweight-obese. Researchers found:
• Chemotherapy dosing was capped in 2 patients; all others initiated full weight-based treatment.
• Overweight-obese patients required more frequent taxane (44.6% vs 25.4%) and any chemotherapy dose reductions (50.5% vs 33.9%).
• pCR was attained in 29.2% of patients.
• For obese patients, any chemotherapy dose reduction was significantly associated with increased odds of not attaining pCR.
Citation: Raman R, Mott SL, Schroeder M, Phadke S, Masri JE, Thomas A. Impact of body mass index and actual weight based neoadjuvant chemotherapy doses on pathologic complete response in operable breast cancer. [Published online ahead of print June 22, 2016]. Clin Breast Cancer. doi:10.1016/j.clbc.2016.06.008.
This Week's Must Reads
Must Reads in Breast Cancer
Gender Images & Social Expectations in BC Diagnosis, Cancer; ePub 2018 Sep 24; Kim, Glassgow, et al
Predicting Mammography Adherence by Income Level, Women’s Health Issues; ePub 2018 Aug 8; Gathirua-Mwangi, et al
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al